Product Status and Market Potential
Beyond Air Pipeline & Market Size
Product | Indication | Development Status |
Key Dates* | US Sales Potential** |
Worldwide Sales Potential** |
---|---|---|---|---|---|
LungFit PRO | Acute viral pneumonia (including COVID-19) | Pilot studies in progress | Pilot study data 2H20 | N/A | N/A |
LungFit GO | Nontuberculous mycobacteria (NTM) lung infection | Pilot phase | Pilot study start 4Q20 Self-administration at home |
>$1B | >$2.5B |
LungFit GO | Severe exacerbations due to lung infections in COPD patients | Pre-clinical | Pilot study start 2H21 | >$2.5B | >$6B |
Nitri*All dates are based on projections and appropriate financing, anticipated first launch on global basis pending appropriate regulatory approvals
**All figures are Company estimates for peak year sales: Global Sales Potential includes US Sales Potential